Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.
The last earnings update was 171 days ago.
Discounted Cash Flow Calculation for BST:0LW using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method. We use
analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
BST:0LW DCF 1st Stage: Next 5 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Neovacs's share price is below the future cash flow value, and at a moderate discount (> 20%).
Neovacs's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Neovacs's earnings available for a low price, and how does
this compare to other companies in the same industry?
Neovacs's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Neovacs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Neovacs's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Miguel Sieler has been the Chief Executive Officer at Neovacs S.A. since October 17, 2013. Mr. Sieler served as the Chairman and Chief Executive Officer of Bayer Group in France since 1998 until 2008. He served as CEO Circle, Life Sciences and prior to that as a Venture Partner at the firm. Mr. Sieler served in various senior positions at Bayer AG, Leverkusen, (Germany) from 1975 to 2008. He joined Bayer AG, Leverkusen, (Germany) in 1975 for an international career which started at the group headquarters in Germany. He further served in various senior management positions in Brussels and Sao Paulo before becoming President of Bayer in Korea. He served as the Chief Executive Officer and Chairman of Bayer Pharma from 1995 to 1998 and at Bayer AG from 1998 to 2008. He serves as the Chairman of Wittycell and Chairman of PlasmaPrime. He serves as the Chairman of Stratoz. He serves as a Director of Neovacs S.A. and Ethypharm SA. He served as a Director of ABIVAX S.A. until September 6, 2015. Mr. Sieler served as a Director of Nexity S.A. from May 10, 2005 to January 27, 2017. Mr. Sieler has over 32 years experience in the chemical and pharmaceutical industry. Mr. Sieler holds a Master of Law from the University of Tubingen, Germany and graduated from the Institut d’Etudes Politiques de Paris, France.
Miguel's compensation has increased whilst company is loss making.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Neovacs management team is about average.
Chief Executive Officer & Director
Chief Scientific Officer
Head of Regulatory Affairs
Chief Medical Officer
Vice President of Pharmaceutical Development
Director of Pharmaceutical Development & Quality Assurance
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Neovacs board of directors is about average.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.